RDPAC药品推广行为准则 - IFPMA

IFPMA商业行为与推广伦理
指导原则
国际制药企业协会联盟会员
公司致力于医疗和生物制药研发事
业,以为患者提供高品质的医疗服
务。国际制药企业协会联盟所代表
的制药企业应按高道德标准、并依
照有关药品和医疗卫生的法律法规
进行药品的推广、销售、和分销。
以下八项指导原则确定了国
际制药企业协会联盟2011年版药
品推广行为准则的基本规定和原
则,适用于国际制药企业协会联
盟的会员公司和其代理,以确保
其与各利益相关方的互动交流行
为是适当的。
1. 确保患者的医疗卫生保障
与福祉是研发制药公司的最高目
标和宗旨;
2. 研发制药公司应遵守相关
药品主管部门对药品的质量、安全
性有效性所制订的最高法定标准;
3. 研发制药公司与各利益相
关方的互动交流活动在任何时候
IFPMA Guiding Principles
on Ethical Conduct and
Promotion
The International Federation of Pharmaceutical
Manufacturers and Associations
(IFPMA) member companies
engage in medical and biopharmaceutical
research in order to benefit
patients and support high-quality
patient care. Pharmaceutical Companies,
represented by IFPMA, promote,
sell and distribute their products in
an ethical manner and in accordance
with all the rules and regulations for
medicines and health care.
The following Guiding Principles set
out basic standards that inform the
2011 IFPMA Code of Practice which
applies to the conduct of IFPMA
Member Companies and their agents,
to help ensure that their interactions
with stakeholders are appropriate.
1. The health-care and well-being of
patients is the first priority for pharmaceutical
companies.
2. Pharmaceutical companies will
conform to high standards of quality,
safety and efficacy as determined by
regulatory authorities.
3. Pharmaceutical companies’ interactions
with stakeholders must at
9
研
制
开
发
制
药
企
业
协
会